Evidence map›Paper›PMID 40751329›Full record

ReviewInternational journal of dermatology2026

MSC-Derived Secretome and Exosomes in Dermatology: Mechanisms, Therapeutic Opportunities, and Scientific Challenges-A Narrative Review.

Marcela da Costa Pereira Cestari, Reinaldo Falavigna Tovo, Daniela Franco Bueno

Abstract readReview
In one paragraph

Review in International journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Exosomes in precision dermatology: From biomarkers to targeted therapeutics in personalized care.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Review
  5. Review
  6. Article
  7. Anti-Inflammatory and Angiogenic Effects of Stem Cell Secretome.International journal of molecular sciences · 2026
    Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Vitiligo.Nature reviews. Disease primers · 2025
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Marcela da Costa Pereira CestariInstituto de Ensino e Pesquisa, Hospital Sírio-Libanês, São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-2935-1969
Reinaldo Falavigna TovoPontifícia Universidade Católica de São Paulo (PUC-SP), Campus Sorocaba, Sorocaba, São Paulo, Brazil.
Daniela Franco BuenoInstituto de Ensino e Pesquisa, Hospital Sírio-Libanês, São Paulo, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stromal cells (MSCs) exert their effects primarily through paracrine signaling via soluble factors and extracellular vesicles (EVs), especially exosomes. These acellular components offer regenerative and immunomodulatory benefits with fewer safety and logistical constraints than cell-based therapies. This study aims to review the composition, mechanisms of action, and dermatologic applications of MSC-derived secretomes and exosomes, including engineered and primed variants, and to discuss translational barriers and safety considerations. A structured literature search was conducted using PubMed and Embase. Studies on molecular content, preclinical and clinical data, engineered EVs, oncologic safety, and regulatory aspects of MSC-derived products in dermatology were included. The MSC secretome includes cytokines, chemokines, growth factors, lipids, and regulatory RNAs that modulate inflammation, promote repair, and support skin homeostasis. Exosomes-particularly those from primed or engineered MSCs-play a key role via targeted microRNA delivery. Preclinical data support efficacy in atopic dermatitis, psoriasis, alopecia areata, vitiligo, chronic ulcers, and photoaging. Pilot clinical trials show promising safety and feasibility for topical or intradermal use. However, product heterogeneity, unclear dosing, long-term oncologic safety, and regulatory challenges persist. MSC-derived secretome and exosomes-especially those from primed or engineered MSCs-offer a promising acellular platform for dermatologic therapy. Clinical translation requires standardization, mechanistic validation, and rigorous safety evaluation through well-designed trials.

Indexed as

ExosomesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationSecretomeSkin DiseasesDermatologyHumansMicroRNAsSkinMicroRNAsdermatosesexosomesextracellular vesiclesmesenchymal stem cell‐derived exosomesmesenchymal stromal cellssecretomeskin diseases

Identifiers

PMID40751329
PMCPMC12783422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.